ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
3 clinical trials · Condition
◉ Watch ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (NCT03972189) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-07-24 |
| Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC (NCT06841874) | Nuvation Bio Inc. | |
| Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors (NCT06797362) | Nuvalent Inc. |
Track ROS1-positive Non-Small Cell Lung Cancer (NSCLC) automatically
Every clearance here is in the API, with alerts when new ones post.